Phase 3 N=189 A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Outcome Responder Rate — 57; 11; 50; 46 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Broad Band Light for the Treatment and Prevention of Senile Purpura
Senile Purpura · Bateman's Purpura
Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions
Phase 3 N=42 A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 42 Participants
Early Phase 1 N=460 Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers
Contraception
Primary: Number of Participants That Were Appropriately Screened for Contraceptive Use — 155; 136; 49; 51 Participants
N/A N=95 Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System
Gastrointestinal Disease · Colorectal Cancer
Primary: The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System — 38; 96 Percentage of Adequate cleansing
Phase 3 N=125 A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 78; 42 Participants
Phase 3 N=325 Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219
Bacterial Vaginosis
Primary: Numbers of Participants With Treatment Emergent Adverse Events and Laboratory Abnormalities — 95; 2 Participants
Phase 3 N=33 Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
Hypertension Secondary to Kidney Transplant
Primary: Number of Participants Who Are Non Dippers — 7; 12 Participants
N/A N=27 Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper
Chronic Pain · Opioid Pain Medication
Primary: Percentage of Patients Who Tolerate Buprenorphine Initiation — 27 Participants
Phase 1 N=24 A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Impaired Renal Function
Primary: Pharmacokinetic Parameters- Plasma AUC0-24 — 16877.94; 32787.41; 64895.29; 15506.68 ng*h/mL
Phase 3 N=1,019 Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Wound Infection · Abscess · Systemic Inflammation
Primary: Early Clinical Response — 403; 416; 100; 86 participants
N/A N=198 Feeding and Transition to Home for Preterms at Social Risk
Premature Birth
Primary: Infant Behavioral Organization — 33.2; 51.8 Orally directed behavioral cues per week
Phase 1 N=102 Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
Acute Bacterial Skin and Skin Structure Infection
Primary: Relative Exposure of AUC of the New Formulation to the Approved Formulation — 1470; 1460 h*µg/mL
Phase 2 N=143 Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
HER2-Positive Breast Carcinoma · Invasive Breast Carcinoma · Metastatic Malignant Neoplasm in the Brain
Primary: Complete Response (CR) Rate in the Brain at 12 Weeks Post-radiation Therapy (RT) Using the RECIST 1.1 Criteria Based on Brain Magnetic Resonance Imaging (MRI) — 5.8; 0…
Phase 2 N=7 A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Asthma After Respiratory Syncytial Virus (RSV) Infection — 0; 0; 0 percentage of participants